Breaking News
Sort by:
Top Post
U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
FDA Granted Orphan Drug Designation to CER-001 for the Treatment of LCAT Deficiency
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to […]
New State-Of-The-Art NHS Hospital To Help Tackle Covid Backlog
A new ‘planned care’ hospital dedicated to non-emergency treatment is due to open in Berkshire […]
Closed Loop Medicine Announces Completion of Precision Medicine Clinical Trial for Patients with High Blood Pressure
Closed Loop Medicine Ltd, a leader in the development of single prescription drug plus digital […]
Detecting Covid-19 Using Only a Smartphone
ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 […]
Evusheld Approved to Prevent COVID-19 in People Whose Immune Response is Poor
A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines […]
Roche Provides Molecular Testing Solutions to Identify and Differentiate SARS-CoV-2 Omicron Variants of Concern
Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a subsidiary within the Roche Diagnostics division, […]
Exosome-based Company Raised 5 M€ for the Development of Its New Biomedicine and Vaccines
Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that […]
Genetic Study Gives Extensive Insights into Severe Covid-19
The world’s largest study of the genetics of critical Covid-19, involving more than 57,000 people, […]
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more